Drug intelligence / Profile preview

Menevit

Development stage: Phase 3
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

Menevit is a male fertility dietary supplement specifically formulated to support sperm health and pre-conception reproductive health. It contains a unique combination of antioxidants, including vitamin C (ascorbic acid), vitamin E (d-alpha-tocopherol), folic acid, zinc, selenium, lycopene, and garlic oil (Allium sativum). These ingredients are intended to reduce oxidative stress and free radical damage in the body, which can negatively impact sperm quality. By supporting antioxidant defenses and providing key micronutrients involved in DNA synthesis and cellular protection, Menevit aims to improve sperm production, motility, morphology, and overall male fertility potential. The supplement is recommended for use by men starting three months prior to attempting conception[1][2][3][5][8][9].

Brand names: Menevit

Beyond the preview

Go deeper on Menevit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Menevit.

Explore the full profile